Analysts’ Recent Ratings Updates for Alkermes (ALKS)

Alkermes (NASDAQ: ALKS) has recently received a number of price target changes and ratings updates:

• 11/20/2025 – Alkermes was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 11/17/2025 – Alkermes had its price target raised by analysts at Truist Financial Corporation from $50.00 to $55.00. They now have a “buy” rating on the stock.
• 11/13/2025 – Alkermes had its price target lowered by analysts at Wells Fargo & Company from $42.00 to $37.00. They now have an “overweight” rating on the stock.
• 11/13/2025 – Alkermes had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $55.00 to $45.00. They now have a “buy” rating on the stock.
• 11/11/2025 – Alkermes is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $50.00 price target on the stock.
• 11/9/2025 – Alkermes was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 11/1/2025 – Alkermes was upgraded by analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating.
• 10/29/2025 – Alkermes had its price target lowered by analysts at Wells Fargo & Company from $44.00 to $42.00. They now have an “overweight” rating on the stock.
• 10/29/2025 – Alkermes had its price target raised by analysts at Needham & Company LLC from $43.00 to $44.00. They now have a “buy” rating on the stock.
• 10/28/2025 – Alkermes was given a new $56.00 price target on by analysts at Jefferies Financial Group Inc.. They now have a “buy” rating on the stock.
• 10/27/2025 – Alkermes had its price target raised by analysts at Mizuho from $40.00 to $45.00. They now have an “outperform” rating on the stock.
• 10/23/2025 – Alkermes had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $45.00 price target on the stock, up previously from $38.00.
• 10/22/2025 – Alkermes had its price target raised by analysts at Royal Bank Of Canada from $45.00 to $47.00. They now have an “outperform” rating on the stock.
• 10/22/2025 – Alkermes had its “neutral” rating reaffirmed by analysts at HC Wainwright.
• 10/22/2025 – Alkermes was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/14/2025 – Alkermes had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity

In related news, EVP Craig C. Hopkinson sold 4,000 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $29.30, for a total transaction of $117,200.00. Following the completion of the transaction, the executive vice president directly owned 65,740 shares in the company, valued at $1,926,182. This represents a 5.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders sold 22,000 shares of company stock valued at $674,390. Company insiders own 4.40% of the company’s stock.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.